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The only licensed dengue vaccine, Dengvaxia®, increases risk of severe dengue when
given to individuals without prior dengue virus (DENV) infection but is protective against
future disease in those with prior DENV immunity. The World Health Organization has
recommended using rapid diagnostic tests (RDT) to determine history of prior DENV
infection and suitability for vaccination. Dengue experts recommend that these assays be
highly specific (≥98%) to avoid erroneously vaccinating individuals without prior DENV
infection, as well as be sensitive enough (≥95%) to detect individuals with a single prior
DENV infection. We evaluated one existing and two newly developed anti-flavivirus RDTs
using samples collected >6 months post-infection from individuals in non-endemic and
DENV and ZIKV endemic areas. We first evaluated the IgG component of the SD BIOLINE
Dengue IgG/IgM RDT, which was developed to assist in confirming acute/recent DENV
infections (n=93 samples). When evaluated following the manufacturer’s instructions, the
SD BIOLINE Dengue RDT had 100% specificity for both non-endemic and endemic
samples but low sensitivity for detecting DENV seropositivity (0% non-endemic, 41%
endemic). Sensitivity increased (53% non-endemic, 98% endemic) when tests were
allowed to run beyond manufacturer recommendations (0.5 up to 3 hours), but
specificity decreased in endemic samples (36%). When tests were evaluated using a
quantitative reader, optimal specificity could be achieved (≥98%) while still retaining
sensitivity at earlier timepoints in non-endemic (44-88%) and endemic samples (31-
55%). We next evaluated novel dengue and Zika RDTs developed by Excivion to detectorg July 2021 | Volume 12 | Article 7038871
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When evaluated visually, the Excivion Dengue RDT had sensitivity and specificity values of
79%, but when evaluated with a quantitative reader, optimal specificity could be achieved
(≥98%) while still maintaining moderate sensitivity (48-75%). The Excivion Zika RDT had
high specificity (>98%) and sensitivity (>93%) when evaluated quantitatively, suggesting it
may be used alongside dengue RDTs to minimize misclassification due to cross-reactivity.
Our findings demonstrate the potential of RDTs to be used for dengue pre-vaccination
screening to reduce vaccine-induced priming for severe dengue and show how assay
design adaptations as well quantitative evaluation can further improve RDTs for
this purpose.Keywords: dengue, rapid diagnostic test, pre-vaccination screening, Zika, dengue vaccineINTRODUCTION
Dengue viruses 1 to 4 (DENV1-4) are mosquito-borne flaviviruses
that cause about 105 million infections globally each year (1).
Approximately 25% of DENV infections cause symptomatic
febrile episodes and ~500,000 result in hospitalizations annually
(1–4). DENV1-4 are considered serotypes (5). Primary infection
with one DENV serotype induces long-term immunological
protection against that specific serotype but can increase the risk
of developing severe dengue disease during secondary infection by
one of the other three serotypes (6, 7). However, after recovering
from a secondary DENV infection, individuals are much less likely
to develop severe dengue disease upon subsequent infection (8).
This has led researchers to conclude that having sequential DENV
infections with two distinct serotypes can induce enduring
immunological cross-protection against all four DENV
serotypes (9).
The only licensed dengue vaccine, Dengvaxia® (Sanofi
Pasteur, Lyon, France), also was shown to provide protection
against future disease in children vaccinated after they have had
at least one prior DENV infection (10). However, Dengvaxia®
increased the risk of severe breakthrough DENV infections in
children vaccinated when seronegative (10). For this reason, in
2018 the Strategic Advisory Group of Experts on Immunization
for the World Health Organization (WHO) recommended using
serological assays, such as rapid diagnostic tests (RDT), to
provide evidence of prior DENV infection and suitability for
vaccination (11). Individuals identified as DENV-seropositive by
such assays would be eligible for vaccination while those
identified as DENV-seronegative would not. In response, in
2019 the Global Dengue and Aedes-transmitted diseases
Consortium (GDAC) recommended that assays have optimal
specificity (≥98%) and sensitivity (≥95%) when used for this
purpose, with a minimum specificity and sensitivity of 90% (12).
When testing for DENV serostatus, “specificity” refers to the
ability of a test to accurately identify those who are truly DENV-
naïve as negative. In the context of dengue pre-vaccination
screening, high specificity is required to avoid vaccinating
individuals who are truly naive and putting them at risk (12,
13). Conversely, “sensitivity” refers to the ability of that test to
accurately identify those who have had a prior DENV infection asorg 2positive. High sensitivity in dengue pre-vaccination screening
assays maximizes detection of individuals with a single prior
DENV infection who would benefit from vaccination because
they are at greater risk for developing severe dengue disease (6). In
2019, Sanofi Pasteur, the developer of Dengvaxia®, evaluated the
specificity and sensitivity of four dengue RDTs (Bio-Rad RDT
Dengue IgA/IgG, CTK Biotech OnSite Dengue IgG/IgM, SD
BIOLINE Dengue IgM/IgG, and GenBody Dengue IgG/IgM)
and observed high specificity overall (>98%) but lower
sensitivities (40-70%) (14). Further, all four dengue RDTs failed
to detect antibodies in individuals with DENV neutralizing
antibody titers of <1:100, the group at greatest risk for future
severe dengue (6). Sensitivity was also low (0-32%) for sera from
individuals with DENV neutralizing antibody titers of 1:100-
1:500 (14).
Moreover, the performance of a given RDT varies depending
on the setting in which it is being used. Dengvaxia is
recommended for individuals age 9 years and above, primarily
in endemic areas. If information about seroprevalence in the target
population is available, measuring the probability that a positive
test result is truly positive (positive predictive value, PPV), and a
negative test result is truly negative (negative predictive value,
NPV), can aid in determining acceptable levels of misclassification
(12, 13). In 2019, the GDAC recommended RDTs have a PPV and
NPV of ≥95%, with a minimum of ≥90% (12). Using samples that
are reflective of the settings in which the RDT will be used is
important when calibrating RDT positivity cutoff values.
Another challenge for the diagnostic performance of dengue
RDTs is the target antigen: most dengue RDTs use DENV1-4
recombinant envelope (E) protein, a primary target for
neutralizing antibodies. However, antibodies targeting the E
protein are highly cross-reactive, especially those targeting the
fusion loop, which is both immunodominant and highly
conserved across flaviviruses (15, 16). In the evaluation by
Sanofi Pasteur, cross-reactivity in dengue RDTs was observed
for individuals with prior Zika virus (ZIKV) infection (14). Given
the structural and antigenic similarity of DENV and ZIKV, their
co-circulation in Asia, Africa, and the Americas, and the recent
ZIKV pandemic in 2014-2017, dengue RDT cross-reactivity for
ZIKV-positive samples is of concern (16). More importantly,
since it is unknown whether individuals with a single prior ZIKVJuly 2021 | Volume 12 | Article 703887
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harmed by vaccination with Dengvaxia®, for the time being these
individuals must be excluded from vaccination (17).
In this study, we evaluated a commonly used dengue RDT
(SD BIOLINE Dengue IgG/IgM) and report for the first time the
evaluation of new dengue and Zika RDTs developed by Excivion,
which use a modified E antigen to distinguish previous DENV
and ZIKV immunity. Further, we tested the effect of modifying
various assay parameters to potentially improve performance for
dengue pre-vaccination screening. We found quantitative
evaluation can improve RDT performance, especially for the
Excivion Zika RDT, but the SD BIOLINE Dengue IgG/IgM and
Excivion Dengue RDT still require further development to be
used as optimal dengue pre-vaccination screening assays.METHODS
SD BIOLINE Dengue IgG/IgM RDT
Test Design and Architecture
The SD BIOLINEDengue IgG/IgMRDT (Bitrodiagnostico, Quito,
Ecuador) detects anti-DENV E protein-specific IgG and IgM
antibodies in serum or plasma. Sample anti-DENV IgG and IgM
antibodies form a complex with recombinant DENV1-4 E proteins
conjugated with a colloidal goldmarker. As Ig-DENVE complexes
move along the strip, they are captured by a corresponding mouse
monoclonal anti-human IgG or IgMantibody (GorM line). Rabbit
anti-DENV IgG are positioned at the control (C) line to confirm
viability of gold marked DENV E proteins.
Clinical Samples and Ethical Statements
The IgG component of the SD BIOLINE Dengue IgG/IgM RDT
was evaluated using samples from two cohorts. Blood samples
(n=24) collected 1-30 years following confirmed DENV and/or
ZIKV infection were provided by adults (age 18-93 years)
recruited in Portland, Oregon with histories of travel to
dengue-endemic areas (Table 1). Infection histories were
confirmed by RT-PCR and/or focus reduction neutralization
test (FRNT), as described previously (18). Signed consent was
obtained from subjects prior to sample and data collection under
a protocol approved by the Oregon Health & Science University
Institutional Review Board (IRB) (IRB# 10212). In a separate
study, serum samples (n=69) were provided by participants in
the EcoDess cohort in Borbón, Ecuador (Table 1). Participants
ranged in age from 2-60 years old, with an even proportion of
individuals of each sex. Samples were collected in October 2018,
~four months after the high DENV transmission season. DENV
seroprevalence in this population was estimated to be 64%.
DENV serostatus was measured using the Dengue PanBio IgG
ELISA, using cutoff values established by DENV1-4 PRNT titers:
DENV-naïve (<0.2 units), DENV-primary (0.2-0.9) and DENV-
secondary (>0.9) (19). ZIKV serostatus was measured with the
gold-standard ZIKV non-structural protein 1 blockade-of-
binding assay (inhibition ≥50% was defined as positive) (20).
The IRBs of the University of Michigan and the Universidad San
Francisco de Quito approved the EcoDess Study. All individuals
over age 18 provided informed consent. Parents providedFrontiers in Immunology | www.frontiersin.org 3informed consent for children under age 18, and all children
age 6 and older also provided oral assent.
Test Evaluation and Data Collection
The SD BIOLINE Dengue IgG/IgM RDT was used as
recommended by the manufacturer. Images were collected of
the RDT strip at 0.25, 0.5, 0.75, 1, 1.5, 2, and 3 hours using a
standardized light source with an iPhone 6 camera positioned
15cm above each test. IgG band positivity was evaluated visually
by having independent analysts classify RDT results as negative
(0), ambiguous (0.5), and positive (1). For the Oregon cohort,
each sample was tested in two independent experiments, and a
blinded analyst evaluated all images. For the EcoDess cohort,
three independent, blinded analysts evaluated each image. We
report average consensus values across analysts (values >0.5 are
positive). Quantitative IgG band pixel intensity was measured
from images using the EBImage package in R (21). Background
pixel intensity of the RDT strip was subtracted from the IgG
band. Higher values indicate stronger signal.
Excivion Dengue RDT and Zika RDT
Test Design and Architecture
DENV1-4 and ZIKV E proteins were engineered to contain a
sequence-programmed N-linked glycosylation of the fusion loop
(USPatent ApplicationNo.16/303,588) (Figure 1). The baculovirus-
expressed fusion-loop hyperglycosylated exodomain E antigens
(abbreviated FL-glycosylated E) were produced in Tni cells (US
Patent Application No. 16/615,788). The primary DENV1-4 and
ZIKV FL-glycosylated E antigen targets contained a C-terminally
located hexahistidine tag to allow arrest at a line of monoclonal anti-
His-tag antibody on the nitrocellulose test strip. The sample pad
additionally contained an excess amount of non-His-tagged FL-
glycosylated DENV or ZIKV E antigen to adsorb out residual
cross-reactive antibodies directed at sites other than the fusion loop
and block a false signal.
To construct each RDT, nitrocellulose (MDI Advance
Microdevices, grade 150CNPH-N-SS40) was laminated onto
250 mm adhesive backing card (Lohmann) and striped with 0.3
mg/mL ReadyTag anti-6 His (BioXcell, cat. no. RT0266) as the test
line and 1 mg/mL human IgG (Sigma-Aldrich, cat. no. 18640) with
acid blue dye as the control line. The conjugate pad (Ahlstrom,
grade 6615) was pre-treated in a solution containing 0.1 M Tris-
HCl, pH 8.0, 0.5% bovine serum albumin and 0.25% Tween-20.
Gold colloid (40 nm, BBI Solutions) was conjugated to anti-human
IgG Mab (Eastcoast Bio, cat. no. HM295) at 3.5 µg/mL in 25 mM
borate buffer, pH 9.0 followed by blocking by adding 10% bovine
serum albumin in water at a final concentration of 0.5%. After
washing and centrifugation the gold conjugate was resuspended to
give an effective concentration of 10 gold units per microliter. The
conjugate was sprayed using a nebulizer onto the previously
prepared and dried conjugate pad so that there were 3.5 µl gold
conjugate per test. For the DENV RDT, the sample pad (Ahlstrom,
grade 8951) was striped with His-tagged DENV1–4 FL-glycosylated
E antigens (25 ng of each per test) and and Strep-tag II ZIKV FL-
glycosylated E antigen (1 µg per test) in PBS buffer (Sigma-Aldrich,
cat. no. P4417) as a single line at 0.5 µl/mm. For the ZIKV RDT, the
sample pad was striped with His-tagged ZIKV FL-glycosylated EJuly 2021 | Volume 12 | Article 703887
Echegaray et al. Rapid Tests for Prior Dengueantigen (50 ng per test) and Strep-tag-II DENV2 FL-glycosylated E
antigen (10 µg per test) in PBS buffer at 1.5 µl/mm. In both RDTs,
acid blue dye was added to the solution at 0.5% to facilitate
visualization of the striping procedure. An absorbent pad
(Whatman, CF5) was laminated to the distal end of the backing
card with a 1-2 mm overlap with the previously laminated
nitrocellulose. The gold-coated conjugate pad was laminated
proximal to the nitrocellulose with a 1-2 mm overlap, and finally
the antigen striped sample pad was positioned upstream of the
conjugate pad with a 1-2 mm overlap. The fully laminated 250 mm
cards were cut into 5 mm individual test strips using a Kinematic
cutter and then assembled into plastic lateral flow cassettes. Tests
were packaged in a foil pouch containing cassettes, desiccant, and a
separate squeeze bottle of buffer and stored at 4° C in the dark
until used.Frontiers in Immunology | www.frontiersin.org 4Clinical Samples and Ethical Statements
The Excivion Dengue RDT was initially evaluated using samples
from acute/convalescent confirmed dengue cases and recent
infections. The first set of acute and early convalescent (days 1-
21 post-symptom onset) deidentified clinical samples were used
by the Naval Infectious Diseases Diagnostic Laboratory at the
Naval Medical Research Center, and included samples provided
by Naval Medical Research Unit Two (NAMRU-2) (Phnom
Penh, Cambodia) and the Naval Medical Research Unit Six
(NAMRU-6) (Lima, Peru) under approved human use
protocol #: PJT-17-06 (Table 1). Past infection history and/or
serostatus was determined by CDC Trioplex real-time RT-PCR
and dengue IgM and IgG ELISAs. ELISA-positive samples were
tested using the CDC dengue PRNT against DENV2, DENV3,
and DENV4 (positive defined as PRNT90 titer of ≥10) or DENVTABLE 1 | Description of cohorts and samples used for evaluating each rapid diagnostic test.
Group Sample characteristics Origin Age/seroprevalence Confirmation test used
Samples used to evaluate the SD BIOLINE Dengue IgG/IgM RDT
Oregon resident DENV
immune cohort
Total n=24 Portland, Oregon USA Adults (ages 18-93) RT-PCR, Focus Reduction
Neutralization Test(DENV-naïve = 5)
(DENV-positive = 16)
(ZIKV-positive = 3)
Collected 1-30 years post
infection
EcoDess cohort Total n=69 Borbón, Ecuador Children and adults (ages 2-60) Dengue PanBio IgG ELISA
(DENV-naïve = 21) Seroprevalence: 64% ZIKV non-structural protein 1
blockade-of-binding assay(DENV-positive = 44)
(ZIKV-positive = 4)
Collected ~4 months after high
DENV transmission season




Total n=12 N/A N/A Multiple DENV ELISA and RDT tests
(DENV-naïve = 1)
(DENV-positive = 11)








Acute and early convalescent
samples (1-21 days post
symptom onset)
Samples used to evaluate the Excivion Dengue RDT
ECUAVIDA Study Total n=115 Quininde, Ecuador Children (age 8) Abcam DENV ELISA and ZIKV ELISA
(DENV-naïve = 41) Seroprevalence: 64%
(DENV-positive = 74)





Total n=52 Managua, Nicaragua Children (ages 2-14) DENV inhibition ELISA, ZIKV NS1
blockade-of-binding assay, RT-PCR
and/or virus isolation, Neutralization
assay
(DENV-naïve = 5) Seroprevalence in 2004: 86%
2015: 32%(DENV-positive = 33)
(ZIKV-positive = 14)
Collected 6-12 months post
infection










Collected 6-12 months post
infectionJuly 2021 | Volume 12 | Article 703887
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independent evaluation was completed using the SeraCare
Dengue Mixed Titer AccuSet™ Performance Panel (0845-
0074), which consisted of 21 single collection-event serum
samples (anti-DENV IgG positive, IgG and IgM positive, and
negative) from multiple individuals in Honduras and India
(Table 1). An informed consent form was signed by the donor,
the donor’s next of kin, and/or an authorized agent or a legal
agent in accordance with applicable laws and regulations.
Full evaluation of the Excivion Dengue and Zika RDT was
performed with samples from two endemic pediatric cohorts in
Managua, Nicaragua at the University of California, Berkeley. The
dengue serum/plasma set (n=52) and the Zika set (n=40)were from
children 2-17 years of age (n=74 unique samples) who had
confirmed dengue or Zika cases (n=5 had only neutralization-
assay confirmed inapparent infections) and for whom likely prior
DENV and ZIKV infections could be determined (17, 23, 24)
(Table 1). Children in the community-based cohort were
followed longitudinally as they experience their first and
subsequent DENV and ZIKV infections (25, 26). In the hospital-
based study, children enroll upon disease presentation (27). All
samples were collected 6-12 months post-infection. Infecting virus
was confirmed by RT-PCR, virus isolation, or a serological
algorithm for the small subset of PCR-negative cases (23). DENV
serostatus and DENV infections were confirmed by testing paired
annual samples by the DENV inhibition ELISA and/or reporter-
virus based neutralization assay (6, 28, 29). ZIKV serostatus and
ZIKV infections weremeasured in paired annual samples using the
ZIKV inhibition ELISA and ZIKVNS1 BOB (20). Individuals were
classified as naïve if they entered the studyDENV-seronegative and
experienced no infection events. Primary versus secondary DENV
infection was evaluated based on the number of observed prior
DENV infections or confirmed dengue cases in the cohort study or
by confirmed dengue case and convalescent anti-DENV inhibition
ELISA titer (>1:2560, based on cutoffs determined for the gold-
standard hemmaglutination inhibition assay) in the hospital studyFrontiers in Immunology | www.frontiersin.org 5(27, 28). Seroprevalence in children 9 years of age in this population
(the age of eligibility forDengvaxia) was 86.6% in 2004 but dropped
over time to 32.2% by 2015 (30). The Nicaragua Pediatric Dengue
Cohort Study and Pediatric Dengue Hospital-based Study were
reviewed and approved by the institutional review boards of the
University of California, Berkeley, and the Nicaraguan Ministry of
Health. Parents or legal guardians of all subjects provided written
informed consent, and subjects ≥6 years old provided assent.
TheExcivionDengueRDTwas also testedusing a representative
set of serum samples collected betweenAugust 2014 andDecember
2016 from 115 healthy children 8 years of age participating in
routine visits in the ECUAVIDA birth cohort in the Quininde
district in Esmeraldas, Ecuador (Table 1). DENV seroprevalence
for children 6-10 years of age in this populationwas 64-67% in 2015
(31). Zika emerged in Ecuador in late 2015 and caused a nation-
wide epidemic in the spring of 2016 (n=18 samples were collected
after the emergence of Zika). DENV serostatus wasmeasured using
the Abcam Human Anti-Dengue virus IgG ELISA Kit (ab108728).
ZIKVserostatuswasmeasuredusing theAbcamanti-Zikavirus IgG
ELISA kit (ab221844) and the anti-Zika virus IgM ELISA kit (m-
capture) (ab213327) (Abcam, Cambridge, UK). None of the
samples collected before the emergence of Zika were ZIKV-IgG
positive (0/11 tested) while 14/18 collected after the emergence of
Zika were positive. The IRBs of the Hospital Pedro Vicente
Maldonado and the Universidad San Francisco de Quito
approved the study protocol. Informed written consent was
obtained from a parent and minor assent from the child.
Test Procedure and Data Collection
Serum/plasma (5 µL) was added to the sample port and
incubated 1-5 minutes at room temperature. Tests were chased
with 120 µL of running buffer containing PBS, 0.025% Tween-20
and 0.5% polyethylene glycol, 20K (Sigma-Aldrich). All tests
were run at room temperature for 0.5 hours before visual and
quantitative data collection. For the Nicaragua samples, images
of the test strip were also collected using the iPhone 6 by 1-3A
B
C
FIGURE 1 | Sequence alignment of the highly conserved fusion loop region of the E proteins for distinct flaviviruses compared to the Excivion DENV1-4 and ZIKV
fusion loop-glycosylated antigens. (A) Sequence homology between ZIKV, DENV1-4, West Nile virus, Japanese encephalitis virus, and yellow fever virus as
previously described (15). Sequences of DENV1-4 (B) and ZIKV (C) used for the Excivion Dengue and Zika RDTs, with position of the N-linked glycosylation sequon
boxed in black.July 2021 | Volume 12 | Article 703887
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1 hours. To evaluate reproducibility for the Nicaragua samples,
10 samples were run independently in separate tests and a subset
of tests was measured twice using the ChemBio Cube portable
lateral flow test reader.
Test Evaluation and Data Collection
Qualitative IgG band positivity was evaluated independently by
SeraCare Life Sciences (now LGC) for the Dengue Mixed Titer
Accuset™ Performance Panel. For the NMRC samples, the tests
were performed and evaluated blindly in duplicate by two
independent operators. Discrepancy in result interpretation was
resolved using a third independent observer. Analysts assigned
band intensity according to a scale from 0-5 (0= no band to 5= very
strong band). The average value is reported. For the Nicaragua
samples, one operator conducted all tests. Two independent
analysts qualitatively evaluated IgG band positivity, with each
reporting a value of 0 for negative, 0.5 for ambiguous, and 1 for a
positive test result. The average value was reported and values >0.5
were considered positive and ≤0.5 as negative. Quantitative IgG
band positivity for the ECUAVIDA and Nicaragua study samples
was calculated using the ChemBio Cube portable lateral flow test
reader. Higher values indicate stronger signal.
Data Visualization and Statistical Analyses
Individual samples were grouped by shared DENV and ZIKV
infection histories based on the reference and/or gold-standard
assays used for each cohort. All individual datapoints are plotted,
withmedian and interquartile range intervals presented as summary
statistics. Sensitivity and specificity were evaluated by comparing all
DENV-seronegative samples (including primary ZIKV) to all
DENV-seropositive samples. For some cohorts, we performed a
secondary analysis comparing all DENV-negative samples only to
primaryDENV-positive samples. Sensitivity and specificity for visual
measures of IgG band positivity were evaluated using contingency
tables in GraphPad Prism 8 software. P-values and statistical
significances were computed using Fisher’s exact test. For
quantitative measures of IgG band positivity, pixel intensity
positivity cutoff values and confidence intervals were derived using
receiver-operating characteristic (ROC) curves using the hybrid
Wilson/Brown method at each timepoint using R and Prism. Pixel
intensity positivity cutoff values were then selected according to the
GDAC optimal (≥98%) or minimum (≥90%) specificity (12). All
sensitivity and specificity values at each timepoint were plotted in
Prismandfit curveswere generated using smoothing spline curves or
simple linear regressionwhen≤3 timepointswere analyzed. PPVand
NPV were calculated using the seroprevalence estimates for the
corresponding age group and time of collection of samples in
each cohort.RESULTS
SD BIOLINE Dengue IgG/IgM RDT
We first evaluated the performance of the SD BIOLINE Dengue
IgG/IgM RDT to detect prior DENV infections in travelersFrontiers in Immunology | www.frontiersin.org 6recruited in Portland, Oregon who experienced virologically
(RT-PCR) and/or serologically (FRNT) confirmed DENV and
ZIKV infections while traveling to an endemic area. Serum from
DENV-naïve individuals who had not visited endemic areas were
also tested. The RDT was performed as recommended by the
manufacturer, with test positivity evaluated visually at 0.25
hours. We found that the 5 DENV-negative individuals (2
yellow fever vaccinee recipients and 3 individuals with one
prior ZIKV infection, ZIKV+) were consistently negative
(Figure 2A), yielding a test specificity of 100%. However, none
(0/16) of the individuals with history of one (DENV+ primary)
or multiple prior DENV infections (DENV+ secondary) were
detected by the SD BIOLINE Dengue IgG/IgM RDT, yielding a
sensitivity of 0% (Figure 2B).
In preliminary analyses using control sera, we had observed that
the IgG line turned positive in some sampleswhen tests were allowed
to run for longer than recommended. We tested the hypothesis that
detection of historical DENV infections would improve with time by
reading the test at serial intervals of 0.25, 0.5, 0.75, 1, 1.5, 2, and 3
hours. All DENV-negative samples remained negative at all
timepoints (specificity: 100%) (Figure 2A). However, even at later
timepoints, only a subset of DENV+ primary samples (5/12) were
positive, with differences in positivity by serotype (lower for DENV1
and DENV4 than DENV2 and DENV3, Figure S1). Sensitivity for
this groupwas 0% between 0.25 and 1.5 hours and only reached 42%
when tests were read at 3 hours (Figure 2B). Overall, sensitivity
including all DENV-positive samples increased at later timepoints
but only reached 53% percent by 3 hours (Figure 2B).
As an alternative approach to improvedengueRDTperformance,
we tested whether measuring IgG intensity quantitatively would
enable identification of optimal cutoff values for distinguishing
positive from negative samples. Band pixel intensity was measured
from images of the test strip using R. Using this approach, DENV-
negative samples maintained lower band intensity values overall,
whereas we detected a continuous increase in band intensity over
time for samples with a history of DENV infection (Figures 2C, D).
Quantitative evaluation enables selecting positivity cutoff values
based on assay performance criteria, and for dengue pre-
vaccination screening, specificity should be prioritized. Thus, we
evaluated sensitivity after setting the specificity according to the
GDAC recommended optimum (≤98%) andminimum (≤90%). (In
this instance, the only specificity ≤90% was 100% and thus the same
value is shown for both specificity cutoffs.) Using this approach, for
both specificity levels, sensitivitywasmuchhigher at early timepoints
(44% at 0.25 hours, 88% at 0.5 hours, 81% at 0.75 hours) than when
evaluated visually (0%) (Figure 2D vs. 2B). Although still below the
desired sensitivity of 95% proposed byGDAC, this demonstrates the
potential benefit of using quantitative readers to maximize detection
of DENV-positive individuals.
To evaluate the performance of the SD BIOLINE IgG/IgM
RDT in a DENV and ZIKV-endemic setting, we tested healthy
samples collected during the low-DENV transmission season
from 69 individuals ages 2-60 participating in a dengue and Zika
cohort study in Esmeraldas, Ecuador. Given that no gold-
standard was available, DENV serostatus was determined using
the PanBio DENV IgG ELISA using cutoff values established forJuly 2021 | Volume 12 | Article 703887
Echegaray et al. Rapid Tests for Prior Denguethis assay using the FRNT as previously described (19). ZIKV
serostatus was defined using the ZIKV NS1 BOB assay, an assay
that has been extensively evaluated and is highly specific (20).
When each RDT was evaluated visually, DENV-seronegative
samples (n=25) were negative at earlier timepoints but became
ambiguous after 1-2 hours (Figure 3A), with specificity dropping
from 100% at 0.25-0.5 hours to 80% at 1 hour. DENV-
seropositive samples (n=44) became more positive over time
(Figure 3B), with sensitivity of 41% at 0.25 hours (primary only:
16%) but reaching 96% when read at 1 hour (primary only: 79%).
When instead the RDT was evaluated quantitatively, specificityFrontiers in Immunology | www.frontiersin.org 7values could be maintained at the levels recommended by GDAC
(≥98% and ≥90%) while sensitivity at 0.25 hours remained high
(57% and 70%, respectively) (Figures 3C, D). Sensitivity varied
with time beyond 0.25 hours but was relatively stable and above
55% when using the minimum specificity ≥90%.
Because this cohort is based in an endemic area where dengue
vaccines might be used, we were also able to consider the
performance of the assay with respect to local seroprevalence,
which was used to estimate PPV and NPV. The PPV was 100% at
≥98% specificity and was 92% at ≥90% specificity, reaching the
optimal 95% at 1.5 and 3 hours (Figure S2-A). NPV was higher0.2
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FIGURE 2 | Evaluation of the IgG component of the SD BIOLINE Dengue IgG/IgM RDT using samples from the Oregon traveler cohort. (A, B) Visual readings for
IgG band positivity evaluated in two independent experiments (average consensus value shown as individual dots) at multiple timepoints. Medians and interquartile
ranges are shown as summary statistics. Data are plotted separately for (A) DENV-naïve (flavivirus naïve or yellow fever vaccine recipients) and ZIKV+ (prior ZIKV
infection but not DENV infection) samples and (B) DENV+ primary (primary DENV infection with one of the four serotypes) and DENV+ secondary (multiple prior
DENV infections or prior DENV and ZIKV infections). Corresponding specificity and sensitivity values (dots) are shown for analyses using all DENV-positive samples
(blue) versus only primary DENV-positive samples (pink) with 95% confidence intervals (vertical bars) for each timepoint. Smoothing spline curves are used to
visualize trends over time. (C, D) Equivalent to A and B, but with quantitative evaluation of RDT tests performed using R, measured as IgG band pixel intensity. Data
again are grouped by infection history and timepoint. Specificity was set to the optimal value (≤98%) or minimum value (≤90%) recommended by GDAC, although for
this dataset, the only specificity ≤90% was 100% and thus the same value is shown for both analyses; corresponding sensitivity values are shown.July 2021 | Volume 12 | Article 703887
Echegaray et al. Rapid Tests for Prior Denguewhen using optimal specificity (≥98%) and peaked at 1 hour
(87%) but never reached the minimum of 90%, as recommended
by GDAC. Overall, when tests were evaluated visually, sensitivity
increased with time at the expense of specificity, limiting reading
of the RDT to earlier timepoints. Quantitative evaluation enabled
the tests to reach recommended specificity and PPV, while also
improving sensitivity and NPV.
Excivion Dengue RDT
Other flaviviruses can induce antibodies that target the
conserved E protein fusion loop and result in false positive
dengue RDT results. Such cross reactivity became an urgent
concern after the Zika epidemic, given the close antigenic
relatedness of DENV and ZIKV (16). To address the need for
a dengue RDT that sensitively and specifically detects remote
prior DENV infection for use in a mass dengue vaccinationFrontiers in Immunology | www.frontiersin.org 8campaign, Excivion developed a novel lateral flow dengue RDT
using DENV1-4 E proteins in which two asparagine-linked
glycans were inserted into E fusion loop (Figure 1). The
glycan blocks antibodies from binding the conserved fusion
loop without disrupting the overall structure of the E protein,
leaving other E epitopes accessible. Further modifications were
made to the test design to overcome cross-reactivity, including
incorporation of excess glycan-blocked ZIKV E protein to
preabsorb cross-reactive antibodies to epitopes outside the
fusion loop. We first evaluated how the Excivion Dengue RDT
performed as a standard diagnostic assay using acute and
convalescent samples from confirmed dengue and Zika cases
(1-21 days post symptom onset) tested at the Naval Infectious
Diseases Diagnostic Laboratory at the Naval Medical Center.
Infections were confirmed by RT-PCR and IgM and IgG ELISA.
All ELISA-positive samples were further tested using either the0.2
5 0.5 0.7
















































































































































































































FIGURE 3 | Evaluation of the IgG component of the SD BIOLINE Dengue IgG/IgM RDT using samples from the EcoDess cohort in Esmeraldas, Ecuador. (A, B) Average
visual readings for IgG band positivity evaluated in one experiment by three separate analysts at multiple timepoints (dots show individual points, groups are summarized by
medians and interquartile ranges). Data are plotted separately for (A) DENV-naïve and ZIKV+ only samples and (B) DENV-positive only with either primary or secondary
DENV immunity, or DENV+ and ZIKV+ samples. Corresponding specificity and sensitivity values (dots) are shown for analyses including all DENV-positive samples and only
primary DENV-positive samples, with 95% confidence intervals (vertical bars) for each timepoint. Specificity and sensitivity values are shown to the right, with estimates fitted
using smoothing splines to visualize trends. (C, D) Equivalent to (A, B), but with quantitative evaluation of RDT tests using R, measured as IgG band pixel intensity.
Specificity was set to optimum (≥98%) and minimum (≥90%) values, and corresponding sensitivity values are shown.July 2021 | Volume 12 | Article 703887
Echegaray et al. Rapid Tests for Prior DengueCDC PRNT against DENV2, DENV3, and DENV4 (positive:
PRNT90 titer of ≥10) or DENV microneutralization tests. None
of the 12 DENV-negative samples were positive by the Excivion
Dengue RDT, yielding a specificity of 100%. Notably, 3 primary
ZIKV infection samples, which were negative by DENV
neutralization test, were also negative in the Excivion Dengue
RDT. Further, the Excivion dengue RDT detected 17 out of 18
DENV-positive samples for an overall sensitivity of 94%
(Table 2). The performance of the Excivion dengue RDT was
then independently compared to other dengue IgG ELISAs and
RDTs using the SeraCare Dengue Mixed Titer Accuset™
Performance Panel (n=11). The Excivion dengue RDT had
higher sensitivity (100%) for detecting samples likely to have
had recent (IgM and IgG) or historic (IgG only) DENV
infections compared to the SD BIOLINE Dengue Duo RDT
(18%) and the PanBio IgG RDT (9%) (Table 3). Further, the
Excivion dengue RDT was as sensitive for detecting DENV-
seropositive samples as five commercially available DENV IgG
ELISAs (Table 3).
We performed a full evaluation of the Excivion Dengue RDT
using samples collected six or more months after confirmed
DENV and ZIKV infections from children participating in
pediatric cohort and hospital studies in Managua, Nicaragua.
Dengue and Zika cases were confirmed by RT-PCR and/or virusFrontiers in Immunology | www.frontiersin.org 9isolation, with a subset confirmed by serological algorithm.
Inapparent DENV and ZIKV infections were confirmed by
DENV and ZIKV iELISA, DENV neutralization assay, and/or
ZIKV NS1 BOB on paired annual samples. Most samples were
from children with primary DENV and ZIKV infections (n=32),
the most difficult samples to classify. When evaluated visually at
0.5 hours, 3/5 DENV-naïve and 12/14 primary ZIKV infection
samples were negative by the Excivion Dengue RDT, with a total
specificity of 79% (Figure 4A). Additionally, 12/18 primary
DENV samples were positive (sensitivity of 67%) and 14/15
secondary DENV infection samples were positive, for a total
sensitivity of 79% (Figure 4B). Sensitivity also differed by
serotype, with the highest sensitivity for DENV2 (Figure S3).
When the Excivion Dengue RDT was evaluated quantitatively
and specificity was set to ≥98%, sensitivity reached 49% at 0.5
hours and further increased with time (52% at 0.75 hours, 75% at
1 hour) (Figures 4C, D). At a specificity of ≥90%, sensitivity was
high and further increased with time, reaching 81% at 1 hour.
We also considered the performance of the Excivion Dengue
RDT in the context of DENV seroprevalence in 9-year-old
children in Nicaragua, which dropped from 86.6% in 2004 to
32.2% by 2015 (30). When seroprevalence was high, PPV was
high (100%), but NPV was lower across timepoints and
specificities (29%-68%). When seroprevalence was lower, PPVTABLE 2 | Preliminary evaluation of the Excivion Dengue RDT to classify acute and early convalescent DENV and ZIKV infection samples.
Sample ID Sample confirmation Infection history DENV RDT score ZIKV PRNT 90 DENV Neut titer
28523 NHS Naïve 0 <10 <20a
28696 NHS Naïve 0 <10 <20a
28697 NHS Naïve 0 <10 <20a
28962 NHS Naïve 0 <10 <20a
1183 PCR-/DENV ELISA- Naïve 0 ND ND
1184 PCR-/DENV ELISA- Naïve 0 ND ND
1208 PCR-/DENV ELISA- Naïve 0 ND ND
1213 PCR-/DENV ELISA- Naïve 0 ND ND
1214 PCR-/DENV ELISA- Naïve 0 ND ND
PT1-2017 PCR ND/PRNT+ ZIKV+ 0 160 <10
778 PCR-/PRNT+ ZIKV+ 0 78 <10
530 PCR-/PRNT+ ZIKV+ 0 266 <10
574 PCR-/PRNT+ DENV+ZIKV+ 0 358 10
970 PCR-/PRNT+ DENV+ZIKV+ 1 217 >80
389 PCR-/PRNT+ DENV+ZIKV+ 1.5 25 >80
29430 NHS DENV+ZIKV+ 2 20 320a
555 PCR-/PRNT+ DENV+ZIKV+ 3 118 >80
375 PCR-/PRNT+ DENV+ZIKV+ 3.5 214 >80
1136 PCR-/PRNT+ DENV+ZIKV+ 4 40 >80
6219c DEN1 DENV+ZIKV+ 4 >320 10240a
21203c DEN1 DENV+ZIKV+ 4.5 10 5120a
FPI04237 DEN2 DENV+ZIKV+ 4.5 10 40960a
FPI05679 DEN2 DENV+ZIKV+ 4.5 10 81920a
FPI05163 DEN2 DENV+ZIKV+ 4.5 20 81920a
1184c DEN1 DENV+ZIKV+ 4.5 80 10240a
618 PCR-/PRNT+ DENV+ZIKV+ 4.5 492 >80
FPI10111 DEN2 DENV+ 5 <10 20480a
6720c DEN1 DENV+ZIKV+ 5 40 10240a
21702c DEN1 DENV+ZIKV+ 5 80 20480a
FPI10014 DEN2 DENV+ZIKV+ 5 >80 >162840a
Sensitivity 17/18 (94%)
Specificity 12/12 (100%)July 2021 | Volume 12aDENV microneutralization test, otherwise DENV2-4 PRNT90.| Article 703887
Echegaray et al. Rapid Tests for Prior Dengueand NPV values remained the same when specificity was set
to ≥98%, but PPV dropped (<85%) while NPV rose (84-91%) at
specificities ≥90% (Figure S2-B). Overall, the Excivion Dengue
RDT had lower than ideal specificity when evaluated visually but
was able to achieve high sensitivity, including when evaluated
quantitatively and when requiring high specificity.
We further evaluated the Excivion Dengue RDT in a cohort of
healthy eight-year-old children participating in the ECUAVIDA
cohort in Esmeraldas, Ecuador. The cohort is representative of the
populationwhere Dengvaxiamight be used, with seroprevalence of
64-67%. Because no gold-standard assays were available, DENV
seropositivity wasmeasured using the Abcam dengue ELISA, while
ZIKV positivity was measured using the Abcam ZIKV ELISA.
When evaluated quantitatively and at a specificity of ≥90%, the
Excivion dengue RDT had a sensitivity of 64%, while at a specificity
of ≥98%, sensitivity was 38% (Figure 5). However, at ≥98%
specificity, PPV was 97% and NPV 72%, surpassing the PPV
recommended by GDAC (Figure S2-C). Overall, the Excivion
Dengue RDT had lower than ideal sensitivity when detecting
remote prior DENV infections but had high PPV and NPV
within the seroprevalence context of this cohort.
Excivion Zika RDT
Individuals with primary ZIKV immunity are at increased risk of
future symptomatic and severe dengue disease (17). However, it is
not yet known whether individuals with primary ZIKV immunity
and no prior DENV infection will benefit fromDENV vaccination,
as it is possible that Dengvaxia could further increase their future
risk of severe dengue (32). Because dengue RDTs can be affected by
cross-reactive immunity induced by ZIKV, for DENV-ambiguous
results, it may be valuable to simultaneously test for ZIKV-specific
antibodies using a separate assay. We evaluated the Excivion Zika
RDT, which uses a similar design to the Excivion Dengue RDT,
with sera from children with well-characterized prior ZIKV and
DENV infections in the same pediatric studies in Managua,
Nicaragua. When the Excivion Zika RDT was evaluated visuallyFrontiers in Immunology | www.frontiersin.org 10at 0.5 hours, 3/10 samples classified as having prior DENV
infections were positive by the Excivion Zika RDT, for a
specificity of 70% (Figure 6A). However, all 30/30 samples
classified as ZIKV-positive were positive by the Excivion Zika
RDT, with a sensitivity of 100% (Figure 6B). When evaluated
quantitatively, sensitivity increased from 93% at 0.5 hours to 100%
at 1 hour (Figure 6D)whilemaintainingoptimal (≥98%) specificity
(Figures 6C, D). At minimum specificity (≥90%), sensitivity was
perfect at all timepoints (100%).DISCUSSION
Currently, there is not a licensed assay that can quickly, easily,
and accurately measure DENV immunity in the context of a
mass vaccination program. In this study, we evaluate the
performance of the SD BIOLINE Dengue IgG/IgM RDT to
detect remote prior DENV infections using non-endemic and
endemic samples. We also provide the first report of dengue and
Zika RDTs developed by Excivion, present their novel design,
and evaluate their performance. To try to improve sensitivity and
specificity, we further analyzed the effect of developing RDTs for
longer than the recommended time and evaluating RDT
positivity using quantitative readers. We found that when
RDTs were evaluated visually and developed for longer periods
of time, increases in sensitivity were offset by decreases in
specificity. In contrast, with quantitative evaluation, specificity
values meeting the GDAC criteria (≥98% or ≥90%) could be
ensured while also achieving higher sensitivity for detecting
endemic samples for all three RDTs studied.
Most existing dengue RDTs were designed to detect acute and
recent DENV infections in symptomatic patients and thus are
calibrated to facilitate disease diagnosis in populations with high
prevalence of anti-DENV immunity. Using samples from both
endemic and non-endemic areas, we found that an existing dengue





















infection (IgM & IgG)
6.12 4.77 1.83 7.87 9.65 + + +++
5.07 4.51 1.64 7.87 8.54 + – +++
4.47 4.16 1.74 7.87 8.03 – – +++
0.75 3.10 1.74 0.89 4.48 – – ++
Historic DENV
Infection (IgG only)
3.46 3.81 1.62 3.55 7.35 – – +++
1.85 3.50 1.94 2.67 7.52 – – +++
1.48 3.83 1.85 2.37 7.57 – – +++
1.04 3.77 2.07 1.54 6.93 – – +++
0.37 1.17 1.32 0.62 2.12 – – +
0.39 1.16 1.09 0.41 4.22 – – +++
0.28 2.97 1.84 0.91 4.89 – – +
DENV-naïve 0.05 0.26 0.25 0.23 0.43 – – –
Sensitivity 2/11 (18%) 1/11 (9%) 11/11 (100%)July 2021 | Volume 12“-” = negative.
“+” = low positivity.
“++” = medium positivity.
“+++” = high positivity.| Article 703887
Echegaray et al. Rapid Tests for Prior Denguewhen used as a screening assay for DENV serostatus in healthy
subjects. TheRDTwashighly specific (100%)whenused as directed
(0.25 hours, visually) but had low sensitivity (41%) for detecting
DENV seropositivity in endemic samples and even lower sensitivity
for detecting primary DENV immunity in endemic samples (16%)
and primary or secondary DENV immunity in non-endemic
samples (0%). If the SD BIOLINE Dengue IgG/IgM RDT were
used as directed, individuals with primary DENV immunity, who
are at high risk of future dengue disease andmay benefit most fromFrontiers in Immunology | www.frontiersin.org 11vaccination, would rarely test positive and receive the vaccine (6,
33).When the SD BIOLINEDengue IgG/IgM RDTwas developed
up to 3 hours and evaluated visually, sensitivity increased with time
at the expense of specificity. Because DENV vaccinations are
earmarked for seropositive children in endemic areas, the
inherent trade-off between sensitivity and specificity suggests that
visual evaluation of the SD BIOLINE Dengue IgG/IgM RDT in
endemic settings should be limited to earlier timepoints (before 0.5




















































































































































































FIGURE 4 | Evaluation of the Excivion Dengue IgG RDT using samples from the Nicaragua Pediatric Dengue Cohort and Hospital-based Studies. (A, B) Visual
evaluation of the IgG band positivity in one experiment by two separate analysts (individual dots). Data are grouped by DENV and ZIKV infection history (medians and
interquartile ranges), separated by (A) DENV-naïve and ZIKV+ samples and (B) DENV+ primary and DENV+ secondary samples (including multiple prior DENV and/or
ZIKV infections). Corresponding specificity and sensitivity values (dots) are shown for both analyses of all DENV-positive samples versus only primary DENV-positive
samples. Vertical bars show 95% confidence intervals for each timepoint. (C, D) Equivalent to A and B, but with quantitative evaluation of RDT tests using the
ChemBio Cube lateral flow reader, measured as IgG band pixel intensity at multiple timepoints. Simple linear regressions are used to visualize trends over time.
Optimal (≥98%) and minimum (≥90%) specificity and corresponding sensitivity values are shown.July 2021 | Volume 12 | Article 703887
Echegaray et al. Rapid Tests for Prior Denguespecificity couldbe set to≥98%andstill reachhigher sensitivity (57%)
at0.25hours, demonstrating thepotential valueofusingRDTreaders
to maximize detection of DENV-seropositive individuals.
Aware of the drawbacks of current dengue RDTs, Excivion
designed dengue and Zika RDTs to increase sensitivity and reduce
cross-reactivity to other flaviviruses. Excivion aimed to eliminate
recognition of the cross-reactive fusion loop and used
preabsorption with excess off-target antigen to reduce noise from
cross-reactive epitopes outside the fusion loop. In preliminary
studies, we showed the Excivion Dengue RDT had high
sensitivity (>94%) and specificity (100%) for detecting acute and
early convalescent DENV- and ZIKV-positive samples. When
visually evaluated with samples from children living in DENV
and ZIKV-endemic Nicaragua and Ecuador with remote prior
DENV infections, sensitivity and specificity values were
equivalent, at 79%. However, quantitative evaluation of the
Excivion Dengue RDT enabled prioritization of specificity, and
when specificity was set to ≥98%, sensitivity was high (49%) and
further increased over time. This observation suggests that
alternative cutoff values may make this assay a strong candidate
pre-vaccination screening assay, among the set of assays currently
available. Further, use of quantitative RDT readers developed for a
smartphone or tablet could further aid in improving the
performance of this and other assays, making RDTs more like an
ELISA in low resource settings (34). We also observed that the
Excivion Dengue RDT had high PPV (>97%) in high DENV
seroprevalence settings, although in low DENV seroprevalenceFrontiers in Immunology | www.frontiersin.org 12settings, PPV dipped below target levels (<85%) when specificity
was set only to ≥90%, as is expected (12, 13). These observations
further underscore the importance of prioritizing high specificity
for pre-vaccination screening assays, as population seroprevalence
is dynamic and can fluctuate over time.
It is not yet known whether individuals with primary ZIKV




























































FIGURE 5 | Evaluation of the Excivion Dengue IgG RDT using samples from the
ECUAVIDA Study. (A, B) Quantitative evaluation of RDT tests using the ChemBio
Cube lateral flow reader, measured as IgG band pixel intensity (medians and
interquartile ranges are shown as summary statistics). Data are plotted separately
for (A) DENV-seronegative and (B) DENV-seropositive samples as classified by
Dengue Abcam ELISA. Specificity and sensitivity values (dots) with 95%
confidence intervals (vertical bars) are shown at a single timepoint, with specificity























































































































































FIGURE 6 | Evaluation of the Excivion Zika IgG RDT using samples from the
Nicaragua Pediatric Dengue Cohort and Hospital-based Studies. (A, B) Average
visual readings for IgG band positivity evaluated in one experiment by two
separate analysts (individual dots) at single timepoint (medians and interquartile
ranges are shown). Analyses are grouped by (A) DENV+ samples (primary DENV
infection with one of the four serotypes or multiple prior DENV infections) and
(B) ZIKV+ samples (prior ZIKV infection but not DENV infection). Corresponding
specificity and sensitivity values (dots) with 95% confidence intervals (vertical
bars) are shown. (C, D) Equivalent to A and B, but with quantitative evaluation of
RDT tests using the ChemBio Cube lateral flow reader, measured as IgG band
pixel intensity at multiple timepoints. Optimal (≥98%) and minimum (≥90%)
specificity and corresponding sensitivity values are shown. Simple linear
regressions show temporal trends.July 2021 | Volume 12 | Article 703887
Echegaray et al. Rapid Tests for Prior Denguevaccination, as it is possible that Dengvaxia or other upcoming
dengue vaccines could increase future risk of severe dengue
disease in this group (26, 32). We found the Excivion Zika
RDT sensitivity was high (100%) at all timepoints when
evaluated qualitatively but specificity was low (70%). However,
sensitivity was high (>93%) and increased with time when
evaluated quantitatively while keeping optimal specificity
(≥98%). Because the performance of dengue RDTs can be
affected by cross-reactive immunity induced by ZIKV, these
results demonstrate a potential added value of additional
testing with a Zika RDT, which could help identify those with
only prior ZIKV immunity.
Our study has limitations. While many of our analyses of RDT
sensitivity and specificity were compared to gold-standard assays
(RT-PCR and/or neutralization assay), the EcoDess and
ECUAVIDA cohorts were limited to classification of serostatus
by the PanBio or Abcam Indirect IgG ELISA. A recent study
comparing the PanBio dengue IgG ELISA to the FRNT found
high correspondence, with a specificity of 93% and sensitivity of
95% for detecting DENV serostatus in a pediatric cohort in the
Philippines (19). Thus, while a small proportion of the samples in
the EcoDess and ECUAVIDA cohorts were likely misclassified,
these studies were included because they are representative of the
target populations for dengue vaccination and enabled estimation
of seroprevalence, making it possible to calculate PPV and NPV.
Overall, our evaluation of the SD BIOLINE Dengue IgG/IgM
RDT and first report of the novel Excivion dengue and Zika
RDTs reveal that modifications to these assays can enable them
to meet some but not all of the performance criteria set for
dengue pre-vaccination assays. The modifications that we tested,
including use of unique antigens/epitope targets in the Excivion
RDTs, extension of RDT development time, and application of
quantitative readers, show promise, improving sensitivity while
maintaining high specificity, but likely require further
optimization prior to use in dengue vaccination efforts. The
development of better dengue RDTs remains a high priority for
the currently licensed dengue vaccine and may be important for
future dengue vaccination efforts.DATA AVAILABILITY STATEMENT
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Supplementary Figure 1 | Evaluation of the IgG component of the SD BIOLINE
Dengue IgG/IgM rapid diagnostic test, stratified by primary DENV infecting serotype,
for samples from the Oregon traveler cohort. Columns indicate infecting serotype, top
row shows visual evaluations, and bottom row shows quantitative readings.July 2021 | Volume 12 | Article 703887
Echegaray et al. Rapid Tests for Prior DengueSupplementary Figure 2 | Positive predictive value and negative predictive
value estimates for the EcoDess, Nicaragua, and ECUAVIDA cohorts. Positive
predictive values and negative predictive values using optimal ≥98% specificity
(PPV: light orange dots, NPV: blue squares) and minimum ≥90% specificity
(PPV: dark orange dots, NPV: navy blue squares) at distinct timepoints for the
EcoDess (A), Nicaragua (using seroprevalence estimates from both 2004 and
2015) (B), and ECUAVIDA (C) cohorts. Smoothing splines and simple linear
regressions show trends over time for the EcoDess and Nicaragua cohorts
respectively.
Supplementary Figure 3 | Evaluation of the Excivion Dengue IgG rapid
diagnostic test by primary and secondary DENV infecting serotype in samples from
the Nicaragua Pediatric Dengue Cohort and Hospital-based Studies. Columns
indicate infecting serotype, top row shows visual evaluations, and bottom row
shows quantitative readings.Frontiers in Immunology | www.frontiersin.org 14Supplementary Table 1 | Sensitivity and specificity values at each timepoint for
the Oregon Traveler Cohort evaluated using the SD BIOLINE Dengue IgG/IgM RDT
(estimate and 95% confidence intervals are shown).
Supplementary Table 2 | Sensitivity and specificity values at each timepoint for the
EcoDess Cohort evaluated using the SD BIOLINE Dengue IgG/IgM RDT (estimate and
95% confidence intervals are shown).
Supplementary Table 3 | Sensitivity and specificity values at each timepoint for
the Nicaragua Cohort samples evaluated using the Excivion Dengue RDT (estimate
and 95% confidence intervals are shown).
Supplementary Table 4 | Sensitivity and specificity values at each timepoint for
the Nicaragua Cohort samples evaluated using the Excivion Zika RDT (estimates
and 95% confidence intervals are shown).REFERENCES
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